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Systemicand coronary hemodynamic, metabolic and hu-
moral effects of a new intravenous angiotensin-convert-
ing enzyme inhibitor, enalaprilat, were evaluated in 14
patients with chronic heart failure. Onset of hemody-
namic action occurred within 15 minutes and persisted
for 6 hours. At the time of peak effect, there was a
significant reduction in mean arterial pressure ( - 21%)
and pulmonary capillary wedge pressure ( - 33%). Sys-
temic vascular resistance decreased by 32% and stroke
volume index increased by 20%. These systemic hemo-
dynamic changes indicate improved left ventricular
function. There was a substantial sustained reduction in
rate-pressure product initially without a change in coro-
nary sinus blood flow or myocardial oxygen consump-
tion. There was also reduced myocardial oxygen ex-
traction and augmented coronary sinus oxygensaturation
at 30 minutes and 1 hour. In three patients, abnormal
Angiotensin-converting enzyme inhibitors have been shown
to be effective in the management of chronic heart failure
(1-8). These beneficial effects derive, in part. from de-
creased circulating angiotensin II (9,10). Short- and long-
term hemodynamic and symptomatic improvement occur
after oral captopril and enalapril therapy (1-8,12-17). En-
alapril is the oral, long-acting, synthetic, tripeptide analog
of known angiotensin-converting enzyme inhibitors, but it
does not contain the sulfhydryl moiety (18). Enalapril, how-
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myocardial lactate extraction, present before enalapri-
lat, changed to uptake after enalaprilat, indicating ame-
lioration of myocardial ischemia that was not clinically
manifest. Systemic catecholamine levels and myocardial
catecholamine balance did not change. Plasma renin ac-
tivity increased and plasma aldosterone decreased.
These findings suggest that enalaprilat produces in-
hibition of the angiotensin-converting enzyme and con-
sequent beneficial systemichemodynamicchangesin heart
failure. In some patients with heart failure, silent myo-
cardial ischemia at rest can occur and can be alleviated
with enalaprilat. Decreased myocardial oxygen extrac-
tion, increased coronary sinus oxygen saturation and
lack of expected decrease in coronary sinus blood flow
despite reduced rate-pressure product suggest transient
coronary vasodilation by enalaprilat.
(J Am Coil CardioI1987;9:1131-8)
ever, is a weak angiotensin-converting enzyme inhibitor, a
prodrug that is converted by ester hydrolysis to its active
metabolite, enalaprilat (18). The onset of action of enalapril
and other oral angiotensin-converting enzyme inhibitors is
relatively late. Enaiaprilat is a parenteral angiotensin-con-
verting enzyme inhibitor that has the potential to produce
rapid hemodynamic effects.
In many patients with chronic heart failure, the renin-
angiotensin system is activated. Although the contribution
of enhanced renin-angiotensin activity in maintaining rel-
atively higher systemic vascular tone in these patients has
been documented, its effects on coronary vascular tone have
not been clarified (9-11). The potential exists for angioten-
sin Il-rnediated increased coronary vascular tone in patients
with heart failure, which may produce adverse effects on
coronary hemodynamics and myocardial metabolic func-
tion. Angiotensin-converting enzyme inhibitors, therefore,
may exert beneficial effects on coronary hemodynamics.
0735·10971871$3.50
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The purpose of this study was to determine the systemic
and coronary hemodynamic, metabolic and humoral effects
of intravenous enalaprilat in patients with chronic heart fail-
ure.
Methods
Study patients. The study group comprised 14 patients
(9 men and 5 women aged 44 to 81 years (mean 67) with
chronic heart failure (New York Heart Association func-
tional class III or IV) known to be present for at least 1
year. The cause of heart failure was ischemic heart disease
in eight patients and primary dilated cardiomyopathy in six
patients. No patient had a prior myocardial infarction in the
preceding 3 months. All patients had symptoms of dyspnea
and fatigue with clinical and radiologic signs of pulmonary
venous hypertension and cardiomegaly. The left ventricular
ejection fraction (by two-dimensional echocardiography or
radionuclide scintigraphy) ranged from 20 to 44%.
Study protocol. The study was approved by the insti-
tutional review board and written, informed consent was
obtained from each patient. Patients were studied at rest, in
a nonsedated state. Vasodilators were discontinued at least
24 hours before the study. All patients were maintained on
stable doses of digoxin and diuretics administered during
the evening after completion of the study. In all, dietary
sodium was restricted to 2 g/day for the duration of the
study.
The study was performed in the cardiac care unit. Right
atrial, pulmonary artery and pulmonary capillary wedge
pressures were measured using a triple lumen balloon flo-
tation thermistor catheter. Cardiac output was determined
in triplicate by the thermodilution method using the same
catheter. Arterial pressure was recorded directly by can-
nulation of a radial artery. In 13 of the 14 patients, a double
thermistor coronary sinus catheter (Wilton Webster Labo-
ratories) was introduced percutaneously into the coronary
sinus to measure coronary sinus blood flow by the constant
infusion thermodilution technique and to obtain coronary
sinus venous samples (19,20). To minimize coronary sinus
reflux, the catheter was advanced under fluoroscopic guid-
ance into the midcoronary sinus and its position ensured
with a small bolus of contrast medium. Significant reflux
was further excluded by monitoring the changes in coronary
sinus blood temperature during an injection of 10 cc iced
saline solution into the right atrium, before and at the con-
clusion of the study (21). All patients rested in the supine
position for 30 minutes and blood samples were drawn from
the arterial line for measurement of plasma renin activity
and aldosterone. One set of arterial and coronary sinus ve-
nous blood samples was drawn for norepinephrine and epi-
nephrine levels, oxygen saturations and lactate levels.
After determination of two sets of baseline hemodynamic
measurements, 15 minutes apart, enalaprilat was adminis-
tered by intravenous bolus (1.25 mg to eight patients and
5.0 mg to six patients). Hemodynamic measurements were
repeated at 15 and 30 minutes and at 1, 1Y2, 2, 3, 4, 5 and
6 hours, coronary sinus blood flow and blood sampling for
oxygen saturations and lactate levels were obtained at 30
minutes and I, 1112, and 2 hours and blood sampling for
catecholamine levels, plasma renin activity and aldosterone
level was repeated at 30 minutes and 2 hours.
Measurements. Derived systemic and coronary hemo-
dynamic variables were calculated as follows: stroke volume
index (SVI, ml/rrr') = CUHR, where CI = cardiac index
and HR = heart rate; stroke work index (SWI, g-m/rrr' =
SVI x (MSP - PCWP) x 0.0136, where MSP = mean
systolic arterial pressure and PCWP = mean pulmonary
capillary wedge pressure; systemic vascular resistance (SVR,
dynes-s-cm- 5) = (MAP - RAP)/CO x 80, where MAP =
mean arterial pressure, RAP = mean right atrial pressure
and CO = cardiac output; pulmonary vascular resistance
(PVR, dynesscrnr ') = (MPAP - PCWP)lCO x 80, where
MPAP = mean pulmonary artery pressure; coronary sinus
blood flow (CSBF, ml/min) = [(Tb - Tj)/(Tb - Tm ) -
1] x 1.08 x 46 mllmin, where T, = temperature of blood,
T, = temperature of injectate and Tm = temperature of
mixture of blood and indicator, 1.08 is a constant account-
ting for specific heat and density of both blood and indicator
and 46 mllmin = injection rate of the indicator (5% dextrose
and water) through the Harvard constant infusion pump.
Oxygen saturations were measured with a Coming 175
automated blood and pH analyzer. Lactate concentrations
were measured by enzymatic spectrofluorometric technique
(22). Normal lactate levels are 5 to 18 mg/dl. The metabolic
variables were calculated as follows: oxygen content (vol%)
= oxygen saturation x hemoglobin x 1.34; myocardial
oxygen consumption (MV02 , mllmin) = (arterial - coro-
nary sinus oxygen content) X coronary sinus blood flow
x 10- 3; myocardial lactate extraction (%) = ([arterial -
coronary sinus]/arterial) lactate x 100.
Norepinephrine and epinephrine were measured by ra-
dioisotope enzymatic assay (23). In our laboratory, replicate
measurements of plasma norepinephrine and epinephrine
have a coefficient of variation of 7 and 11%, respectively.
Normal laboratory values in supine subjects are as follows:
norepinephrine, 100 to 550 pg/ml and epinephrine, 35 to
165 pg/ml. Net transmyocardial release of norepinephrine
and epinephrine (pg/ml) were calculated as (arterial - coro-
nary sinus difference [pg/mll) x coronary sinus blood flow
(mllmin). Plasma renin activity was determined by the gen-
eration of angiotensin I and angiotensin I was measured by
radioimmunoassay (24). Plasma aldosterone was measured
by a radioimmunoassay technique (Smith, Kline) (25-28).
Normal values in supine subjects on a low sodium diet are
as follows: plasma renin activity 1.8 to 3.6 ng/ml per h,
and plasma aldosterone 4 to 12 ng/dl.
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Results
Systemic hemodynamics (Fig. 1, Table 1). Onset of
action after an intravenous bolus of enalaprilat occurred
within 15 minutes and persisted to 6 hours. There was a
significant reduction in mean arterial pressure and pulmo-
nary capillary wedge pressure. At peak effect, there was an
increase in cardiac index and stroke volume index, without
significant change in heart rate or stroke work index. One
patient with class IV heart failure and low output state de-
veloped dizziness with a reduction in blood pressure from
107/40 mm Hg at baseline to 85/28 mm Hg at I hour and
a concomitant reduction in cardiac output from 3.72 to 2.60
liters/min after 1.25 mg of enalaprilat.
Coronary hemodynamics and myocardial metabolism
(Fig. 2, Table 2). There was a significant and sustained
reduction in rate-pressure product. Coronary sinus blood
Statistical analysis. Values are represented as the mean
± SO or SEM. A probability (p) value <0.05 was consid-
ered significant. Statistical determinations were performed
using repeated measures analysis of variance for the sys-
temic hemodynamic variables. To evaluate the humoral ef-
fects of enalaprilat, repeated measures analysis of variance
was performed using the log of the variable in question.
Peak effect of enalaprilat was defined recursively from the
mean blood pressure. Baseline mean blood pressure was
initially assumed to represent peak effect. If any of the
subsequent values were 1 SO or less than the previous peak
effect, a new peak effect was defined. To evaluate early
versus late effects of enalaprilat on coronary hemodynamics,
the area under the curve was utilized from baseline to I
hour and then from I to 2 hours.
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Figure 1. Effectsof enalaprilaton systemichemodynamics. Mean
arterial blood pressure (BP), pulmonary capillary wedge pressure
(PCWP) and right atrial pressure (RAP) decreased. Systemic vas-
cular resistance(SVR) decreasedand cardiac index (CI) increased.
Heart rate (HR) did not change significantly. Results are given as
mean change (Ll) from the baseline ± SEM.
Table 1. Changes in Systemic Hemodynamics at Peak Mean Blood Pressure Effect After
Enalaprilat (n = 14)
Baseline Peak Effect
(mean ± SO) (mean ± SO) p Value
HR (beats/min) 80 ± 14 77 ± 14 NS
SBP (mm Hg) 142 ± 28 114 ± 27 <0.0001
OBP (mm Hg) 66 ± 14 51 ± II <0.0001
Mean BP (mm Hg) 91 ± 17 72 ± 15 <0.0001
Mean PAP (mm Hg) 38 ± 12 30 ± 12 <0.0001
PCWP (mm Hg) 24 ± 8 16 ± 6 <0.002
(n = 12)
RAP (mm Hg) 8 ± 5 5 ± 3 <.006
CI (liters/min per rrr') 2.36 ± 0.50 2.76 ± 0.55 <0.003
SVI (ml/rrr') 30 ± 8 36 ± 8 <0.003
SWI (g.mlm 2) 29 ± 14 28 ± 12 NS
(n = 12)
SVR (dynes-s-cm 5) 1.580 ± 400 1.070 ± 300 <0.005
PVR (dynes-s-cm 5) 280 ± 160 250 ± 160 NS
Statistical comparison: peak effect versus baseline. BP = blood pressure; CI = cardiac index; OBP =
diastolic blood pressure; HR = heart rate; PAP = pulmonary artery pressure; PCWP = pulmonary capillary
wedge pressure; PVR = pulmonary vascular resistance; RAP = right atrial pressure; SBP = systolic blood
pressure; SVI = stroke volume index; SVR = systemic vascular resistance; SWI = stroke work index.
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occurred after enalaprilat and persisted for the duration of
observation to 2 hours (Fig. 3).
Humoral effects and catecholamine balance (Fig. 4,
Table 3). Average plasma renin activity and plasma al-
dosterone levels were above normal at baseline, indicating
an activated renin-angiotensin system in these patients. Plasma
renin activity increased and plasma aldosterone decreased
significantly after enalaprilat. There was no significant change
in arterial norepinephrine or epinephrine levels, and trans-
myocardial release of norepinephrine and epinephrine was
also unchanged after enalaprilat.
Discussion
Systemic hemodynamic effects. The results of the pres-
ent study demonstrate that intravenous enalaprilat is an ef-
fective and potent angiotensin-converting enzyme inhibitor.
As also shown by others (29), its onset of action is fairly
rapid, occurring within 15 minutes of administration, and
its duration of effect is usually prolonged and may last for
6 hours.
Hemodynamic evaluation showed a substantial decrease
in left ventricular filling pressures and an increase in stroke
volume and cardiac index indicating improved left ventric-
ular function (Fig. I). Improved cardiac performance re-
sulted at least partly from decreased left ventricular outflow
resistance as arterial pressure and systemic vascular resist-
ance decreased.
This investigation also demonstrates that the rapid atten-
uation of the vasoconstrictive effects of angiotensin II can
be achieved with the use of parenteral angiotensin-con-
verting enzyme inhibitors such as enalaprilat. The temporal
relation between the hemodynamic alterations and the ex-
pected changes in plasma renin activity and aldosterone after
angiotensin-converting enzyme inhibition was obvious. As
plasma renin activity increased and, presumably, angioten-
sin II level decreased, peripheral vascular tone decreased,
explaining the rapid improvement in hemodynamics and
cardiac function. The clinical implication of these results is
that rapid angiotensin-converting enzyme inhibition can be
achieved with enalaprilat with expected humoral and hemo-
dynamic changes. The systemic hemodynamic effects of
enalaprilat appear to be no different from those of other oral
angiotensin-converting enzyme inhibitors such as captopril
(1-4,6,8,12). However, because the onset of the hemo-
dynamic effects of enalaprilat is fairly rapid, it has the
potential to cause rapid improvement in cardiac function
when it is indicated.
Coronary hemodynamics. In this study there was a
significant reduction in rate-pressure product after enala-
prilat. A similar effect has been observed (4,12) after admin-
istration of other angiotensin-converting enzyme inhibitors,
such as captopril, Changes in the other determinants of
myocardial oxygen demand such as contractility and ven-
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flow and myocardial oxygen consumption did not change
initially. There was, however, a trend toward lower coro-
nary sinus blood flow and myocardial oxygen consumption
at jllz and 2 hours after enalaprilat. Myocardial oxygen
extraction decreased and coronary sinus oxygen saturation
increased at 30 minutes and 1 hour. At 2 hours, however,
these changes were not significantly different compared with
control values. Decreased myocardial oxygen extraction and
increased coronary sinus oxygen saturation at 30 minutes
and 1 hour were obvious in 10 of 13 patients. In three
patients with coronary artery disease who were asympto-
matic at the time of study, there was abnormal myocardial
lactate metabolism before enalaprilat, indicating myocardial
ischemia. In all three patients, net myocardial lactate uptake
Figure 2. Effects of enalaprilat on coronary hemodynamics. There
was a sustained reduction in rate-pressure product (RPP) without
a significant change in myocardial oxygen consumption (MV02)
or in coronary sinus blood flow (CSBF). Myocardial oxygen ex-
traction (A-CS02C) decreased and coronary sinus oxygen satu-
ration (CSOzS) increased from baseline to 1 hour, but the effect
was not sustained from 1 to 2 hours. Results are given as mean
change (d) from baseline ± SEM. ARTOzS = arterial oxygen
saturation.
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Table 2. Changes in Coronary Circulation and Myocardial Metabolism After Enalaprilat (n = 13)
Baseline I Hour 2 Hours
(mean ± SO) (mean ± SO) P Value (mean ± SO) p Value
RPP (rnm Hg/min x 10- 3) 11.61 ± 3.18 9.82 ± 3.21 <0.001 9.71 ± 2.99 <0.001
(n '= 14)
MV02 (ml 02/min) 13.1 ± 4.7 11.9 ± 29 NS 11.5 ± 3.1 NS
CSBF (mllmin) 107 ± 35 99 ± 29 NS 95 ± 21 NS
Arterial O2 (%sat O2) 94.2 ± 2.5 93.9 ± 2.4 NS 94.2 ± 2.4 NS
CS O2 (%sat O2) 24.2 ± 7.1 26.4 ± 7.1 <0.04 25.5 ± 4.6 NS
A-CS O2 (vol%) 12.3 ± 1.7 11.8 ± 1.7 0.02 12.0 ± 1.6 NS
Lactate extraction (%) 24.7 ± 40.0 47.8 ± 11.0 NS 42.7 ± 13.6 NS
Statistiical comparison: I hour versus baseline, 2 hours versus baseline. CSBF '= coronary sinus blood flow; CS O2 '= coronary sinus oxygen
saturation; A-CS O2 '= myocardial oxygen extraction; MV02 '= myocardial oxygen consumption; RPP '= right pulmonary pressure; sat '= saturation.
tricular volume were not measured in our patients. Other
studies, however, have suggested that angiotensin-convert-
ing enzyme inhibitors do not possess any direct positive
inotropic effects (4) and that left ventricular volume tends
to decrease with these agents (30). Thus, it is likely that in
our patients there was a decrease in myocardial oxygen
requirements. Therefore, a reduction in coronary sinus blood
flow and myocardial oxygen consumption was expected.
However, in the present study, coronary sinus blood flow
remained unchanged initially with a subsequent tendency to
decreased flow by 2 hours (Fig. 2). These findings suggest
that, initially, coronary blood flow was in excess of meta-
bolic demand. Lack of concomitant decrease of coronary
sinus blood flow with decreased myocardial oxygen re-
quirements suggests direct coronary vasodilation by ena-
laprilat. That there was transient coronary vasodilation was
also evident from the decreased myocardial oxygen extrac-
Figure 3. Effects of enalaprilat on myocardial lactate metabolism
in 13 individual patients. In three patients (open triangles, squares
and circles), abnormal myocardial lactate extraction at baseline
changed to sustained lactate uptake after enalaprilal. In the re-
maining 10 patients, lactate extraction was normal.
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tion and the increased coronary sinus oxygen saturation at
30 minutes and I hour after enalaprilat administration. How-
ever, myocardial oxygen extraction and coronary sinus ox-
ygen saturation almost returned to their baseline values at
2 hours, and concurrently there was a tendency to lower
coronary sinus blood flow and myocardial oxygen con-
sumption. These findings suggest that coronary vasodilation
in response to enalaprilat was transient.
The mechanism for coronary vasodilation remains un-
clear. There was no change in circulating norepinephrine
or transmyocardial norepinephrine release. Thus, with-
drawal of sympathetic activity seems an unlikely explana-
tion. In experimental animals, angiotensin II has been shown
to cause transient coronary vasoconstriction (31). Atten-
uation of the effect of angiotensin II on the coronary vascular
bed remains a potential mechanism for transient coronary
vasodilation. Angiotensin-converting enzyme inhibitors may
Figure 4. Effect of enalaprilat on norepinephrine level and the
renin-angiotensin system. Arterial norepinephrine levels did not
change. Plasma renin activity (e) (ng/ml per h) increased and
plasma aldosterone level (0) (ng/dl) decreased after enalaprilal.
Results are given as mean change from baseline :t SEM.
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Arter ial E (pg/ml)
TMR E (pg/ml x lO~ )
Arter ial NE (pg/rnl)
TMR NE (pg/rnl x 104 )
PRA (ng/ml per h)
PA (ng/dl) (n = 12)
Baseline
(mean ± SO)
40 ± 30
2.9 ± 18
260 ± 140
1.3 ±1.7
5.8 ± 8.3
23.6 ± 16.6
30 Minutes
(mean ± SO)
50 ± 40
- 7.8 ± 16
290 ± 140
1.8 ± 2.2
25.8 ± 30.3
14.2 ± 11.7
2 Hours
(mean ± SD)
50 ± 40
9.0 ± 19
350 ± 490
0.2 ± 6.2
21.1 ± 22.8
12.2 ± 13.2
p Value
NS
NS
NS
NS
< 0.0005
< 0.0005
Statistical comparison: 30 minutes and 2 hours versus baseline . E = epinephrine; NE = norepinephrine ;
PA = plasma aldosterone; PRA = plasma renin activity: TMR = transmyocard ial release .
also cause vasodilation mediated through the release of pros-
taglandin s or decreased metabolism of bradykinin, or both
(18 ,32). Whether enalaprilat also causes coronary vasodi-
lation through this mechanism needs to be determined by
further studies. In our previous studies (4, 12), we observed
that captopril consistently decre ases myocardial oxygen
consumption and coronary sinus blood flow along with de-
creased rate-pressure product, and coronary vasodilation was
not observed. These responses to captopril appear to be
different from those to enalaprilat as observed in this study .
However , in our previous stud ies, the coronary hemody-
namic responses to captopril were determined at the time
of peak effect, usually I V2 to 2 hours after its admini stration;
thus, it is feasible that the initial coronary vasodilatory effect
of captopril was missed in our previous studies .
Silent myocardial ischemia. Of three patients with
coronary artery disease who did not complain of angina at
the time of study, myocardial lactate production occurred
at rest in two and zero lactate extraction in one. In all three
patient s, there was myocardial lactate uptake after enala-
prilat . This amelioration of abnormal myocardial lactate
metabolism persisted during the period of observation. In
the other 10 patients lactate extraction remained normal
(Fig. 3). Myocardial lactate production usually results from
myocardial ischemia or hypoxia (33-41). In isolated heart
preparations, accelerated glycolysis, as induced by insul in
and glucose , may be associated with increased production
of lactate , even if adequate oxygen is available (42,43).
However. in vivo, myocardi al lactate production usually
indicates anaerobic glycolysis resulting from myocardial
ischemia. This observation, therefore , suggests that silent
myocardial ischemia at rest can occur in patients with dilated
cardiom yopathy associated with coron ary artery disease and
that this ischemia can be allev iated by enalaprilat.
The mechanism by which enaLapriLat decreased rest myo-
cardial ischemia in these three pat ients remains unclear.
In animal models captopril was shown (45) to decrease the
extent of myocardial ischemi c injury produced by acute
coronary occlusion (44) . It was suggested that improved
perfusion to the ischemic myocardium with concurrent re-
ducti on in myocardial oxygen requirements was the poten-
tial mechanism for the beneficial effect seen. In our study ,
there was evidence for only transient coronary vasodilation,
but the rate-pressure product was consistently lower after
enalaprilal. Hence, decre ased myocardial oxygen require-
ments must have been contributory . Whether there was also
improved perfusion to the ischemic myocardium cannot be
ascertained from our results.
Neurohumoral changes. As expected , angiotensin-con-
verting enzyme inhibition with enalaprilat was associated
with elevated plasma renin activity due to stimulation of the
negative feedback loop. The aldosterone level decreased
concurrently, presumably because of withdrawal ofthe stim-
ulating effect of angiotensin II on adrenal medullary syn-
thesis and release of aldos terone .
Other studies have reported a reduction in norepinephrine
levels during long-term therapy of chronic heart failure with
captopril (45) . Reduction in norepinephrine levels with en-
alapril, acutely and durin g maintenance therapy, has been
demonstrated in one study (15), but not corroborated by
another study (16). Perhap s the lack of change in norepi-
nephrine levels found in our investigation and that of Kubo
et al. (29), may be the count erbalancing effect of enhanced
sympathoadrenergic activity in response to acute reduction
in blood pressure, overriding the blunting effect on sym-
pathetic activity by angiotensin II withdrawal.
Conclusion. Enalaprilat is a potent parenteral angioten-
sin-converting enzyme inhibitor. It produces fairly rapid
improvement in cardiac performance along with the ex-
pected humoral changes in patients with chronic severe heart
failure and has the potenti al to relieve myocardial ischemia.
Thus, enalaprilat may be useful in the immediate manage-
ment of patients with severe heart failure.
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